Z-2323-2021 Class II Terminated

Recalled by Cytocell Ltd. — Cambridge, N/A

FDA device recall Z-2323-2021 was initiated by Cytocell Ltd. on May 27, 2021 and is designated Class II. Reason for recall: May show unexpected locus specific signals in addition to those at 19p13.3. Users may observe faint additional locus specific signals at 9q34 The recall status is terminated (terminated May 9, 2022). Affected quantity: 23 units.

Recall details

Product Type
Devices
Report Date
Aug 25, 2021
Initiation Date
May 27, 2021
Termination Date
May 9, 2022
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
23 units

Product description

Cytocell LPH019-A E2A (TCF3) Breakapart Probe- In Vitro Diagnostic Analyte specific reagents (ASR's)

Reason for recall

May show unexpected locus specific signals in addition to those at 19p13.3. Users may observe faint additional locus specific signals at 9q34

Distribution pattern

US Nationwide distribution in the states of CA, IL, KY, NY, OH, TX, UT, VA.

Code information

Lots 073004 and 072518 (Probe lot 200918-006).

Source

Dataset
openFDA device recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for Z-2323-2021
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for Z-2323-2021. Report a data issue: hello@regdatalab.com.